Eris Lifesciences Limited Market Cap ($1.82 Billion)
Market Cap & Net Worth: Eris Lifesciences Limited (ERIS)
Eris Lifesciences Limited market cap. Eris Lifesciences Limited (NSE:ERIS) has a market capitalization of $1.82 Billion (Rs168.38 Billion) as of November 5, 2026. Listed on the NSE stock exchange, this India-based company holds position #6293 globally and #287 in its home market, demonstrating a 1.39% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Eris Lifesciences Limited's stock price Rs1215.00 by its total outstanding shares 138583305 (138.58 Million). Also see Eris Lifesciences Limited (ERIS) cash flow conversion for how efficiently the company converts equity into cash flow.
Eris Lifesciences Limited Market Cap History (2017–2026)
Eris Lifesciences Limited market cap history from 2017 to 2026. Data shows growth from $1.15 Billion to $1.82 Billion (8.22% CAGR). Check Eris Lifesciences Limited (ERIS) stock price for real-time trading data and today's change.
Index Memberships
Eris Lifesciences Limited is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY 500
NIFTY500
|
$3.06 Trillion | 0.06% | #253 of 500 |
|
NIFTY MIDSMALLCAP 400
NIFTYMIDSML400
|
$1.11 Trillion | 0.16% | #165 of 400 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$3.14 Trillion | 0.06% | #248 of 750 |
|
NIFTY SMALLCAP 250
NISM250
|
$395.04 Billion | 0.46% | #72 of 250 |
Weight: Eris Lifesciences Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Eris Lifesciences Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Eris Lifesciences Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ERIS shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.06x
Eris Lifesciences Limited's market cap is 0.06 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.29x
Eris Lifesciences Limited's market cap is 0.29 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $1.15 Billion | $7.49 Billion | $2.47 Billion | 0.15x | 0.47x |
| 2018 | $993.57 Million | $8.27 Billion | $2.94 Billion | 0.12x | 0.34x |
| 2019 | $685.37 Million | $9.67 Billion | $2.91 Billion | 0.07x | 0.24x |
| 2020 | $853.18 Million | $10.58 Billion | $2.96 Billion | 0.08x | 0.29x |
| 2021 | $1.13 Billion | $11.93 Billion | $3.55 Billion | 0.09x | 0.32x |
| 2022 | $970.05 Million | $13.26 Billion | $4.06 Billion | 0.07x | 0.24x |
| 2023 | $1.36 Billion | $16.62 Billion | $3.82 Billion | 0.08x | 0.36x |
| 2024 | $2.06 Billion | $19.91 Billion | $3.92 Billion | 0.10x | 0.53x |
| 2025 | $2.26 Billion | $28.79 Billion | $3.52 Billion | 0.08x | 0.64x |
| 2026 | $1.82 Billion | $31.29 Billion | $6.20 Billion | 0.06x | 0.29x |
Competitor Companies of ERIS by Market Capitalization
Companies near Eris Lifesciences Limited in the global market cap rankings as of November 5, 2026. Also see ERIS asset base for a full breakdown of the balance sheet.
Key companies related to Eris Lifesciences Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Eris Lifesciences Limited (2017–2026)
Market capitalization of Eris Lifesciences Limited from 2017 to today. Between 2017 and today, Eris Lifesciences Limited's market cap moved from $1.15 Billion to $ 1.82 Billion, with a yearly change of 8.22%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs1.82 Billion | -19.30% |
| 2025 | Rs2.26 Billion | +9.60% |
| 2024 | Rs2.06 Billion | +50.96% |
| 2023 | Rs1.36 Billion | +40.59% |
| 2022 | Rs970.05 Million | -13.93% |
| 2021 | Rs1.13 Billion | +32.10% |
| 2020 | Rs853.18 Million | +24.48% |
| 2019 | Rs685.37 Million | -31.02% |
| 2018 | Rs993.57 Million | -13.50% |
| 2017 | Rs1.15 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Eris Lifesciences Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.82 Billion USD |
| MoneyControl | $1.82 Billion USD |
| MarketWatch | $1.82 Billion USD |
| marketcap.company | $1.82 Billion USD |
| Reuters | $1.82 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Eris Lifesciences Limited
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as anti"diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women… Read more